Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...
China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...
Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study...
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...
Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...
China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...
China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation...
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has...
China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...
Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up...
Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...
China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...
CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval...
The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s...